Beyaz®: An oral contraceptive fortified with folate

Women's Health

Volumn 8, Issue 1, 2012, Pages 13-19

  Fruzzetti, Franca ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Beyaz ; drospirenone; levomefolate calcium

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL PLUS MEFOLATE CALCIUM; ETHINYLESTRADIOL; FOLIC ACID; PLACEBO;

ACNE VULGARIS; ARTICLE; CONTRACEPTION; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FOLIC ACID BLOOD LEVEL; HUMAN; MULTIPLE CYCLE TREATMENT; NEURAL TUBE DEFECT; PREGNANCY; PREMENSTRUAL DYSPHORIC DISORDER; RISK REDUCTION; TREATMENT RESPONSE;

ANDROSTENES; CALCIUM; CONTRACEPTION; CONTRACEPTIVES, ORAL, COMBINED; DRUG ADMINISTRATION SCHEDULE; ETHINYL ESTRADIOL; EVIDENCE-BASED MEDICINE; FEMALE; GLUTAMATES; HUMANS; NEURAL TUBE DEFECTS; PATIENT SATISFACTION; TETRAHYDROFOLATES;

EID: 83755180484     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/whe.11.68     Document Type: Article

References (53)

1. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal model. Contraception 51, 99-110 (1995).
2. Foidart JM, Oelkers W, Heithecker R. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity: major breakthrough in tomorrow's oral contraception. Gynecol. Snapshot 3, 13-17 (1995).
3. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54, 243-251 (1996). (Pubitemid 26398621)
4. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids 68, 891-905 (2003). (Pubitemid 37532413)
5. Rosenbaum P, Schmidt W, Helmerhorst FM et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur. J. Contracept. Reprod. Health Care 5, 16-24 (2000). (Pubitemid 30321316)
6. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62, 29-38 (2000).
7. Rapkin AJ, Winer SA. Drospirenone: a novel progestin. Expert Opin. Pharmacother. 8, 989-999 (2007). (Pubitemid 351227486)
8. Oelkers W. Drospirenone - a new progestogen with antimineralocorticoid activity, resembling natural progesterone. Eur. J. Contracept. Reprod. Health Care 5(Suppl. 3), 17-24 (2000). (Pubitemid 32173575)
9. Fruzzetti F, Lello S, Lazzarini V et al. The oral contraceptive containing 30 μg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 75, 199-203 (2007). (Pubitemid 46217183)
10. Fruzzetti F, Lazzarini V, Ricci C et al. Effect of an oral contraceptive containing 30 μg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception 76, 190-194 (2007). (Pubitemid 47247660)
11. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Health Care 5, 124-134 (2000). (Pubitemid 30470064)
12. Huber J, Foidart JM, Wuttke W et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur. J. Contracept. Reprod. Health Care 5, 25-34 (2000). (Pubitemid 30321317)
13. Genazzani AR, Pluchino N, Begliuomini S et al. Drospirenone increases central and peripheral A endorphin in ovariectomized female rats. Menopause 14, 1-11 (2007).
14. Paoletti AM, Lello S, Fratta S et al. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 μg of ethinyl estradiol. Fertil. Steril. 81, 645-651 (2004). (Pubitemid 38376123)
15. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61, 105-111 (2000). (Pubitemid 30236331)
16. Cibula D, Karck U, Weidenhammer HG, Kunz J, Marr A, Marr J. Efficacy and safety of a low-dose 21 day combined oral contraceptive containing ethinylestradiol 20 μg and drospirenone 3 mg. Clin. Drug Invest. 26, 143-150 (2006).
17. Gruber DM, Huber JC, Melis GB, Stagg C, Parke S, Marr J. A comparison of the cycle control, safety and efficacy profile of a 21 day regimen of ethinylestradiol 20 μg and drospirenone 3 mg with a 21 day regimen of ethinylestradiol 20 μg and desogestrel 150 μg. Treat. Endocrinol. 5, 115-121 (2006).
18. Apter D, Borsos A, Baumgärtner W et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur. J. Contracept. Reprod. Health Care 8, 37-51 (2003). (Pubitemid 36398865)
19. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24 day combined oral contraceptive containing 20 -micrograms ethinylestradiol and 3 mg drospirenone. Contraception 70, 191-198 (2004). (Pubitemid 39119980)
20. Anttila L, Kunz M, Marr J. Bleeding pattern with drospirenone 3 mg + ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg + ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception 80, 445-451 (2009).
21. Hernadi L, Marr J, Trummer D, De Leo V, Petraglia F. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4 day regimen. Contraception 80, 18-24 (2009).
22. Willis SA, Kuehl TJ, Spiekerman AM, Sulak PJ. Greater inhibition of the pituitary- ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception 74, 100-103 (2006). (Pubitemid 44062466)
23. Mishell DR. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations. Contraception 7, 304-305 (2005).
24. Rapkin AJ, Shelley N, Sorger NS, Winer SA. Drospirenone/ethinylestradiol. Drugs Today (Barc.) 44, 133-145 (2008).
25. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using an oral contraceptive as a treatment for premenstrual symptoms. Psychoneuroendocrinology 18, 273-281 (1993). (Pubitemid 23156341)
26. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med. 53(Suppl. 9), 729-741 (2008).
27. Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet. Gynecol. 106, 492-501 (2005). (Pubitemid 41208780)
28. Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ ethinylestradiol 3 mg/20 μg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs 67, 1749-1765 (2007). (Pubitemid 47263180)
29. Maloney JM, Kunz M, Lee-Sugh S et al. Drosperinone 3 mg/ethinylestradiol 20 μg COC in the treatment of acne vulgaris: lesion count, ISGA. Presented at: 55th Annual Clinical Meeting of the American College of Obstetricians and Gynaecologists. San Diego, CA, USA, 5-9 May 2007.
30. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects. Implications for prevention. JAMA 274, 1698-1702 (1995).
31. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q. J. Med. 86, 703-708 (1993).
32. George L, Mills JL, Johansson AL et al. Plasma folate levels and risk of spontaneous abortion. JAMA 288, 1867-1873 (2002). (Pubitemid 35168142)
33. Perry J, Chanarin I. Intestinal absorption of reduced folate compounds in man. Br. J. Haematol. 18, 329-339 (1970).
34. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 338, 131-137 (1991).
35. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327, 1832-1835 (1992). (Pubitemid 23003073)
36. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 260, 3141-3145 (1988).
37. Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. N. Engl. J. Med. 341, 1509-1519 (1999). (Pubitemid 29526355)
38. Goh YI, Bollano E, Einarson TR, Koren G. Prenatal multivitamin supplementation and rates of congenital anomalies: a meta-analysis. J. Obstet. Gynaecol. Can. 28, 680-689 (2006).
39. Sen S, Manzoor A, Deviasumathy M, Newton C. Maternal knowledge, attitude and practice regarding folic acid intake during the periconceptional period. Public Health Nutr. 4, 909-912 (2001). (Pubitemid 32666996)
40. O'Leary M, Donnell RM, Johnson H. Folic acid and prevention of neural tube defects in 2000 improved awareness - low peri-conceptional uptake. Ir. Med. J. 94, 180-181 (2001). (Pubitemid 32677250)
41. Wright JD, Bialostosky K, Gunter EW et al. Blood folate and vitamin B12: United States, 1988-1994. Vital Health Stat. 11(243), 1-78 (1998).
42. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285, 2981-2986 (2001). (Pubitemid 32550116)
43. Ray JG, Meier C, Vermeulen MJ, Boss S, Wyatt PR, Cole DE. Association of neural tube defects and folic acid food fortification in Canada. Lancet 360, 2047-2048 (2002). (Pubitemid 36026586)
44. Lopez-Camelo JS, Orioli IM, Dutra MD et al. Reduction of birth prevalence rates of neural tube defects after folic acid fortification in Chile. Am. J. Med. Genet. 135, 120-125 (2005). (Pubitemid 40769959)
45. Institute of Medicine Food and Nutrition Board. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B 6, Folate, Vitamin B 12, Pantothenic Acid, Biotin, and Choline. National Academy Press, Washington, DC, USA (1998).
46. Lamers Y, Prinz-Langenohl R, Moser R, Pietrzik K. Supplementation with [6S] 5 methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women. Am. J. Clin. Nutr. 79, 473-478 (2004). (Pubitemid 41115593)
47. Venn BJ, Green TJ, Moser R, McKenzie JE, Skeaff CM, Mann J. Increases in blood folate indices are similar in women of childbearing age supplemented with [6S] 5 methyltetrahydrofolate and folic acid. J. Nutr. 132, 3353-3355 (2002). (Pubitemid 35304243)
48. Troen AM, Mitchell B, Sorensen B et al. Unmetabolized folic acid in plasma is associated with reduced natural killer cell cytotoxicity among postmenopausal women. J. Nutr. 136, 189-194 (2006). (Pubitemid 43156507)
49. Prinz-Langenohl R, Bramswig S, Tobolski O et al. [6S] 5 methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C->T polymorphism of methylenetetrahydrofolate reductase. Br. J. Pharmacol. 158, 2014-2021 (2009).
50. Lamers Y, Prinz-Langenohl R, Bramswig S, Pietrzik K. Red blood cell folate concentrations increase more after supplementation with [6S] 5 methyltetrahydrofolate than with folic acid in women of childbearing age. Am. J. Clin. Nutr. 84, 156-161 (2006). (Pubitemid 44699180)
51. Pietrzik K, Prinz-Langenohl R, Lamers Y, Wintergerst ES, Bramswig S. Randomized, placebo-controlled, double-blind study evaluating the effectiveness of a folic acid containing multivitamin supplement in increasing erythrocyte folate levels in young women of child-bearing age. S. Afr. J. Clin. Nutr. 18(Suppl.), abstract (2005).
52. Marr AJ, Sampson-Landers C, Diefenbach K, Trummer D, Bart S, Blode H. Folate and homocysteine levels after 24 weeks administration of Yaz + levomefolate calcium 0.451 mg. Presented at: The 11th Congress of the European Society of Contraception and Reproductive Health. The Hague, The Netherlands, 19-22 May 2010 (Abstract P178).
53. Diefenbach K, Trummer D, Ebert F, Lissy M, Rohde B, Blode H. Changes in folate levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg co-administration. Presented at: The 11th Congress of the European Society of Contraception and Reproductive Health. The Hague, The Netherlands, 19-22 May 2010 (Abstract P176).